Zuckermann Marc, Kawauchi Daisuke, Gronych Jan
Brief Funct Genomics. 2017 Jan;16(1):25-33. doi: 10.1093/bfgp/elw021. Epub 2016 Jun 5.
Advanced biological technologies allowing for genetic manipulation of the genome are increasingly being used to unravel the molecular pathogenesis of human diseases. The clustered regulatory interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) technology started a revolution of this field owing to its flexibility and relative ease of use. Recently, application of the CRISPR/Cas9 system has been extended to in vivo approaches, leveraging its potential for human disease modeling. Particularly in oncological research, where genetic defects in somatic cells are tightly linked to etiology and pathological phenotypes, the CRISPR/Cas technology is being used to recapitulate various types of genetic aberrations. Here we review murine cancer models that have been developed via combining the CRISPR/Cas9 technology with in vivo somatic gene transfer approaches. Exploiting these methodological advances will further accelerate detailed investigations of tumor etiology and treatment.
先进的生物科技能够对基因组进行基因操作，越来越多地被用于揭示人类疾病的分子发病机制。成簇规律间隔短回文重复序列/CRISPR相关蛋白（CRISPR/Cas）技术因其灵活性和相对易用性，引发了该领域的一场革命。最近，CRISPR/Cas9系统的应用已扩展到体内研究方法，利用其在人类疾病建模方面的潜力。特别是在肿瘤学研究中，体细胞中的基因缺陷与病因和病理表型紧密相关，CRISPR/Cas技术正被用于重现各种类型的基因畸变。在此，我们综述了通过将CRISPR/Cas9技术与体内体细胞基因转移方法相结合而开发的小鼠癌症模型。利用这些方法上的进展将进一步加速对肿瘤病因和治疗的详细研究。
